Isocitrate Dehydrogenase 2 (IDH2) Mutation Analysis
Isocitrate dehydrogenases IDH1 and IDH2, are NADP dependent cytoplasmic and mitochondrial enzymes that are involved in cellular glucose metabolism and oxidative damage control. IDH mutations, primarily involving codons R132 in IDH1 and R172 in IDH2, lead to a reduction of enzyme activity. Mutations also result in the gain of a neomorphic ability to generate the oncometabolite R (-)-2-hydroxyglutarate, which is believed to contribute to tumorigenesis and cause genome-wide epigenetic changes that characterize the glioma CpG island methylator phenotype (G-CIMP).
Approximately 34% of individuals with a central nervous system (CNS) tumors have a somatic mutation in the IDH1 or IDH2 genes. Mutations are present in the majority of low-grade diffuse (WHO grade II) and anaplastic (WHO grade III) astrocytic, oligodendroglial, and mixed oligodendroglial neoplasm, as well as in secondary glioblastomas. In contrast, IDH mutations are observed in only 5% of primary glioblastomas. Mutations in IDH1 and IDH2 have also been observed in up to 22 % of acute myelogenous leukemias, which concurrently display a dramatic increase in 2HG, supporting the neoenzymatic activity.
IDH1 mutation has been shown to be a strong, independent prognostic biomarker not only in glioblastomas, but in diffuse gliomas of lesser grades as well. While the IDH1 mutation conveys a better patient outcome, it does not predict a better response of the glioma to chemotherapy. In addition to their prognostic value, identification of IDH mutations could be used diagnostically. Analysis of IDH1/ 2 mutations could be utilized in the separation of primary and secondary glioblastomas or in the challenge of differentiating pilocytic astrocytoma from glioblastoma.
- As an aid in diagnosis and prognosis of a diffuse glioma
- Good marker for central nervous system tumor classification
- As an aid in differential diagnosis of chondroid bone tumors
- Stratifying prognosis of acute myeloid leukemia
No reportable alterations were identified in the targeted regions of the IDH2 gene
Formalin fixed paraffin embedded (FFPE) tumor samples (tissue blocks) and slides.
FFPE samples are stable in room temperature for longes.
- Curr Opin Neurol. 2018 Dec;31(6):727-732. [PMID: 30239358]
- Cancer. 2017 Dec 1;123(23):4535-4546. [PMID: 28980701]
- Science. 2008 Sep 26;321(5897):1807-12. [PMID: 18772396]
- N Engl J Med. 2009 Feb 19;360(8):765-73. [PMID: 19228619]
- Clin Cancer Res. 2010 Mar 1;16(5):1597-604. [PMID: 20160062]